Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-1293 vs Lantus in T2DM
NCT02059187Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Feb 2014
- Primary completion
- Mar 2015
- Modality
- Recombinant Proteins and Enzymes
01
Overview
A Phase 3 trial of lusduna nexvue in type 2 diabetes mellitus (T2DM), sponsored by Merck & Co.. Started Feb 2014; status: completed.
02
Drugs
lusduna nexvue
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02059187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02059187.